Novo Nordisk and Orbis Partner on $1.4 Billion Deal for Oral Obesity Drug Discovery
What happened
Novo Nordisk signed a drug-discovery and licensing agreement with Orbis Medicines, valued at up to $1.4 billion. The collaboration focuses on developing oral therapies for cardiometabolic diseases that are traditionally treated with injections. The partnership utilizes Orbis’ AI-enabled nGen platform to discover orally bioavailable macrocycles. This strategic move gives Novo Nordisk another route to expand its oral cardiometabolic pipeline.
From insidermonkey.com
Why it matters
The deal provides a significant financial upside for Orbis, validating its AI platform for drug discovery. For Novo Nordisk, the agreement strengthens its competitive position in oral cardiometabolic medicines as the market increasingly values oral treatments.
From insidermonkey.com
Who's involved
- Novo NordiskDanish pharmaceutical company entering the licensing agreement to develop oral therapies.
- OrbisJapanese mail-order company whose AI platform is being licensed for drug discovery.
Keep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Orbis
Japanese mail-order company
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.